Congress Introduces SAFE Drugs Act of 2025, Expanding FDA Oversight of Compounded GLP-1 Drugs and Telehealth Providers - dykema.com
The SAFE Drugs Act of 2025, introduced in Congress, would expand FDA oversight of compounded GLP-1 drugs and telehealth providers, potentially affecting compounding pharmacies and telehealth practices.
Aforeworn detected this change in the Pharmaceutical Manufacturing (FDA/DEA) space on August 16, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated Medium urgency. Compounding pharmacies (especially 503B outsourcing facilities), telehealth providers prescribing or dispensing compounded GLP-1 drugs, and their supply chains. should confirm how it applies to their specific situation before acting. There is a time constraint attached: Not specified; bill is introduced, not yet law.. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Pharmaceutical Manufacturing (FDA/DEA) continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
Proposed legislation to expand FDA oversight of compounded GLP-1 drugs and telehealth providers, likely adding new compliance requirements for manufacturing, labeling, and distribution.
Who it affects
Compounding pharmacies (especially 503B outsourcing facilities), telehealth providers prescribing or dispensing compounded GLP-1 drugs, and their supply chains.
What you must do
Monitor legislative progress and prepare for potential new FDA compliance requirements, including possible registration, reporting, and quality standards for compounded GLP-1 products.
Deadline
Not specified; bill is introduced, not yet law.
Never miss a change like this again
Aforeworn watches Pharmaceutical Manufacturing (FDA/DEA) around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Pharmaceutical Manufacturing (FDA/DEA)
- TX SB 18: Relating to prohibitions on the manufacture and provision of abortion-inducing drugs, including the jurisdiction of and effect of certain judgments by courts within and outside this state with respect to the manufacture and provision of those drugs, and to protections from certain counteractions under the laws of other states and jurisdictions; authorizing qui tam actions.
- FDA Proposes New Registration and Listing Pathway for Distributed Manufacturing and Aligns Foreign Establishment Obligations With Current Law - arnoldporter.com
- FDA issues first cGMP warning letter citing AI misuse in pharmaceutical manufacturing - manufacturingchemist.com
- FDA makes groundbreaking decision to waive clinical efficiency studies for monoclonal antibody biosimilars - Manufacturing Chemist
- FDA Clarifies Policies for Pharmacy Compounders of GLP-1 Products - foley.com